Commitments and Contingencies (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2021 |
Jun. 30, 2020 |
Jun. 30, 2021 |
Jun. 30, 2020 |
|
| Operating lease expense | $ 14,571 | $ 14,620 | $ 28,033 | $ 28,103 |
| Description of study drug and supplemental financial support | The Company will provide study drug and supplemental financial support for the clinical trial averaging approximately $2 million to $3 million per year | |||
| Operating lease monthly payment | $ 4,487 | |||
| XOMA Ltd | ||||
| Option and license agreement description | that could reach up to $14.925 million if the Company achieves all milestones | |||
| GEIS | ||||
| Clinical-related expenses | $ 300,000 | $ 200,000 | $ 700,000 | $ 200,000.0 |
| Onxeo S.A | ||||
| Option and license agreement description | the option agreement includes clinical, regulatory, developmental and sales milestones that could reach up to $108 million if the Company achieves all milestones, and escalating royalties on net sales from 5% to 10%. | |||
| Option and license agreement fee | $ 1,000,000 | |||